Literature DB >> 27816215

Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile.

Twisha S Patel1, Sandro Cinti2, Duxin Sun3, Siwei Li3, Ruijuan Luo3, Bo Wen3, Brian A Gallagher4, James G Stevenson5.   

Abstract

With the threat of significant morbidity and mortality following an influenza pandemic, stockpiling of antiviral agents such as oseltamivir is recommended. Shelf-life extension was explored to maximize use of an existing stockpile. This analysis demonstrated that oseltamivir retains potency defined by United States Pharmacopeia acceptance criteria beyond the labeled expiration date.
Copyright © 2017 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27816215     DOI: 10.1016/j.ajic.2016.09.024

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

1.  Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.

Authors:  Leo Y Lee; Jie Zhou; Paulina Koszalka; Rebecca Frise; Rubaiyea Farrukee; Keiko Baba; Shahjahan Miah; Takao Shishido; Monica Galiano; Takashi Hashimoto; Shinya Omoto; Takeki Uehara; Edin J Mifsud; Neil Collinson; Klaus Kuhlbusch; Barry Clinch; Steffen Wildum; Wendy S Barclay; Aeron C Hurt
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

Review 2.  Influenza antivirals currently in late-phase clinical trial.

Authors:  Paulina Koszalka; Danielle Tilmanis; Aeron C Hurt
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

3.  Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations.

Authors:  Mohammad Vakili; Elida Romano; Vahidreza Darugar; Silvia Antonia Brandán
Journal:  J Mol Model       Date:  2021-11-23       Impact factor: 1.810

4.  Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model.

Authors:  Harry L Stannard; Edin J Mifsud; Steffen Wildum; Sook Kwan Brown; Paulina Koszalka; Takao Shishido; Satoshi Kojima; Shinya Omoto; Keiko Baba; Klaus Kuhlbusch; Aeron C Hurt; Ian G Barr
Journal:  Commun Biol       Date:  2022-09-28

5.  Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir.

Authors:  Y Q Shirleen Soh; Keara D Malone; Rachel T Eguia; Jesse D Bloom
Journal:  Viruses       Date:  2021-06-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.